Home›Explore peptides›Generic vs compounded liraglutide
Generic liraglutide vs compounded liraglutide: what is the difference?
An FDA-approved generic liraglutide is a medicine FDA reviewed and approved as a generic. A compounded drug is not FDA-approved, and a vial sold with a research-use label is a different thing again. “Generic” is a regulatory term with one specific meaning.
On this page
In brief
Should you care? Yes, if a product is described as a “generic” or a “copy” of Victoza or Saxenda, or if a price looks far below the brand. The word tells you nothing unless FDA actually approved the product as a generic.The short version
- Approved generics exist. FDA approved the first generic referencing Victoza on 23 December 2024 and the first referencing Saxenda on 27 August 2025.12
- A generic is not a compounded drug. FDA says so directly: a generic is approved under a specific section of the law, while a compounded drug is not approved by FDA.4
- One of FDA’s own red flags: a seller claiming a compounded drug is the same as an FDA-approved drug.5
Four things sold under one drug name
“Liraglutide” can describe four different kinds of product. They sit in different regulatory categories, and only the first two are FDA-approved medicines.
| Kind of product | FDA-approved? | What FDA says about review |
|---|---|---|
| Brand-name medicine (Victoza for type 2 diabetes, Saxenda for weight management) | Yes | Goes through FDA’s drug approval process, which FDA describes as verifying safety, effectiveness and quality; the label states approved uses and warnings467 |
| Generic liraglutide approved by FDA | Yes, as a generic | FDA requires a generic to be the same as the brand in dosage, safety, effectiveness, strength, stability and quality, and in the way it is taken3 |
| Compounded drug prepared by a pharmacy or outsourcing facility | No | “FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed”4 |
| A vial sold with a “research use only” label | No | Not an FDA-approved medicine. FDA’s page says unapproved GLP-1 versions “do not undergo FDA’s review for safety, effectiveness and quality,” and describes warnings to companies selling unapproved drugs falsely labelled “for research purposes” or “not for human consumption.” The drugs named in that warning are semaglutide, tirzepatide, retatrutide, survodutide and mazdutide; liraglutide is not mentioned on the page5 |
What FDA has approved as generic liraglutide
On 23 December 2024 FDA announced approval of the first generic referencing Victoza (liraglutide injection, 18 mg/3 mL). FDA said the generic’s prescribing information includes the same boxed warning about thyroid C-cell tumors.1 FDA’s later research report records additional generic liraglutide injections approved in April and July 2025, and the first generic referencing Saxenda on 27 August 2025.2
FDA notes that complex drug products such as liraglutide can be more difficult to develop as generics because of their complex active ingredient, formulation or mode of delivery.1 Both brand-name products remain approved.67 FDA also notes generic drugs are “generally more affordable.”1 This page makes no claim about any price or supplier.
What a generic is not
FDA answers the question directly: “Are compounded drugs and generic drugs the same? No.” A generic is approved under section 505(j) of the Federal Food, Drug, and Cosmetic Act and must establish therapeutic equivalence to a brand-name drug, while a compounded drug is not approved by FDA.4 A product is a generic only if FDA approved it as one. A product that is cheaper, shipped in a vial, or described as “the same ingredient” is not a generic for that reason.
What FDA says about compounded GLP-1 drugs
An FDA-approved generic liraglutide now exists, as section 2 describes. FDA recognizes that compounding can serve a real need: a compounded drug might be appropriate if a patient’s medical need cannot be met by an FDA-approved drug, or the FDA-approved drug is not commercially available.5 It also says compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug, and that poor compounding practices can cause serious quality problems such as contamination or the wrong amount of active ingredient.4
On GLP-1 medicines specifically, FDA’s page, which names semaglutide and tirzepatide, describes concerns that apply to injectable compounded products in general:5
- Multiple-dose vials: FDA generally recommends discarding a vial 28 days after first use because contamination risk rises, even if medicine remains.
- Storage in shipping: injectable GLP-1 drugs need refrigeration, and FDA has received complaints of products arriving warm.
- Telehealth red flags FDA lists include claims that the compounded drug is the same as an FDA-approved drug, prices that seem too good to be true, and no screening or prescription by a licensed doctor.
FDA’s guidance for patients is to get a prescription from a doctor and fill it at a state-licensed pharmacy.5 Whether a specific compounded product is lawful depends on rules that change, so this page does not say which are.
Research-use-only vials
“Research use only” is a laboratory labelling category. It is not a certification and it does not make a product a generic or a compounded medicine. See what “Research Use Only” actually means, peptide vendor red flags, and how to read a certificate of analysis. We do not name, rank or recommend any seller.
What you can check
- Ask the dispensing pharmacy whether the product is the brand-name medicine, an FDA-approved generic, or a compounded preparation. These are three different answers.
- Read the label and the package insert. An FDA-approved product comes with prescribing information including the boxed warning.
- Treat a claim that something is “identical to” or “the same as” an approved drug as a prompt to ask who approved that statement. FDA lists it as a red flag.5
- Questions about your own treatment belong with your prescriber or pharmacist.
As of this review
As of 1 October 2026
This page follows the FDA statements and approval dates cited below. FDA’s GLP-1 page was current as of 1 October 2026. We do not state current supply status or which compounded products are permitted, because both change. We will revise and date this page if FDA changes its generic approvals, compounding policy or guidance, or if a reader shows us an error (use the “Report an error” topic on About).
What you can do next
References
- U.S. Food and Drug Administration, news release, “FDA Approves First Generic of Once-Daily GLP-1 Injection to Lower Blood Sugar in Patients with Type 2 Diabetes,” 23 December 2024. fda.gov
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research, “FY 2025 GDUFA Science & Research Report” (liraglutide approvals, including the first generic referencing Saxenda on 27 August 2025). fda.gov
- U.S. Food and Drug Administration, “Generic Drug Facts,” page current as of 1 November 2021. fda.gov
- U.S. Food and Drug Administration, “Compounding and the FDA: Questions and Answers,” page current as of 16 September 2025. fda.gov
- U.S. Food and Drug Administration, “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss,” page current as of 1 October 2026. fda.gov
- Victoza (liraglutide) injection, prescribing information. National Library of Medicine DailyMed. DailyMed
- Saxenda (liraglutide) injection, prescribing information (Medication Guide revised 02/2026; Instructions for Use revised 06/2026). National Library of Medicine DailyMed. DailyMed